Indication
Atherosclerotic Cardiovascular Disease
The Atherosclerotic Cardiovascular Disease pipeline: 143 tracked drugs, 14 approved for this indication.
14 approved / phase 454 Phase 31 Phase 2/333 Phase 26 Phase 1/227 Phase 18 preclinical / unstaged
Compare the share prices of listed companies in Atherosclerotic Cardiovascular Disease →
Total attributable cost
$381.0B
$19,145/patient
Drug spend
$22.7B
$1,139/patient
6% of total cost is drugs
All severities (2015-2018 NHANES cycle) · US